Mount Sinai Hospital

In November 2017, Compugen announced a multi-year research collaboration with Mount Sinai Hospital, under the direction of Miriam Merad M.D., Ph.D., Director of the Precision Immunology Institute and Co-Leader of the Cancer Immunology program and Mount Sinai Professor in Cancer Immunology at the Icahn School of Medicine at Mount Sinai in New York, and a member of Compugen’s Scientific Advisory Board. This collaboration focuses on the research and target validation of selected myeloid candidates discovered by Compugen for their potential to serve as a basis for cancer immunotherapy treatments, including the validation of their role in innate immunity and involvement in tumor biology.


Max 1mb, accepted formats: pdf, doc, docx, rtf
[recaptcha size:compact]
Message Sent. Thank You!